The annual ESGCT conference is renowned for spotlighting breakthrough innovations in gene and cell therapy. It acts as a global stage for companies to showcase the latest scientific and technological achievements impacting their work in the biotherapeutics industry.  

In this context, ArcticZymes salt active nucleases featured in multiple ESGCT presentations, underscoring its critical role in advancing gene therapy innovation. This includes the Austrian Centre of Industrial Biotechnology (acib), an internationally recognized non-profit research centre. 

ACIB's presentation compared ArcticZymes' M-SAN HQ with Benzonase and demonstrated M-SAN HQ's superior ability to break down not just loose DNA but also chromatin (complex DNA structures). This results in a cleaner purification process, producing purer and more effective virus-like particles (VLPs) used in applications such as vaccines. In short, M-SAN HQ optimizes the removal of unwanted materials, making the manufacturing process more efficient. This achievement highlights the ongoing impact of ArcticZymes' enzymes in solving complex bioprocessing challenges and showcases the value of its collaboration with the Austrian Centre of Industrial Biotechnology in optimizing viral vector production.  

As a scientific conference first, to our knowledge, ArcticZymes enabled a live AI-based Q&A for this presentation further demonstrating innovation to ESGCT visitors (link to Q&A below). 

Another presentation, by Oxford Biomedica (OXB), highlights M-SAN's role in enhancing downstream recovery, reducing DNA contamination, and minimizing vector aggregation, resulting in cleaner, higher-quality lentiviral vectors. By degrading chromatin and optimizing DNA clearance at physiological salt levels, M-SAN simplifies workflows and boosts efficiency, which is crucial for regulatory compliance.  

A few quotes from this presentation include:  

"M-SAN demonstrated superior performance compared to the Industry Standard Nuclease when integrated into OXB's LV production process", and "SAN also outperformed the Industry Standard Nuclease when integrated into OXB's LV production" and "Over 10-fold reduction in residual DNA compared to the Industry Standard Nuclease" 

The OXB presentation focus on salt active nucleases serves to reaffirm their importance for improving process efficiency and product quality, both of which contribute to economic gains for them and their customers in the highly competitive landscape of gene therapy. 

"Collaborations with leading institutes like ACIB continue to push the boundaries of what is possible in bioprocessing," said ArcticZymes CEO Michael Akoh. "The exceptional interest around our booth at ESGCT 2024 reaffirms the strong interest in ArcticZymes' solutions, as attendees recognized the tangible benefits our enzymes bring to improving efficiency and product quality in viral vector production. 

More information about ArcticZymes at ESGCT at https://tinyurl.com/AZesgct2024  

For more information, please contact:

ArcticZymes Technologies ASA
CEO, Michael B. Akoh  Tel: +46 (0) 70 262 37 15
ir@arcticzymes.com 

About ArcticZymes Technologies ASA 

ArcticZymes Technologies is a Norwegian life sciences company focused on the development, manufacturing and commercialization of novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large portfolio of patents. 

For more information, please visit the website: www.arcticzymes.com